Recent studies have revealed the existence of bone marrow-derived endothelial progenitor cells (EPCs). The number of circulating EPCs might reflect the pathogenesis of atherosclerosis and progression of cardiovascular diseases (CVDs). The purpose of this study was to evaluate the relationship between the number of EPCs and cardiovascular risk factors.
Recent studies have revealed the existence of bone marrowderived endothelial progenitor cells (EPCs) in peripheral circulation. 1 These cells are involved in postnatal neovascularization and re-endothelialization of injured vessels. 2, 3 Several investigators have demonstrated that EPCs are mobilized from bone marrow by various kinds of angiogenic growth factors, cytokines, and chemokines in response to ischemia or vascular injury. [4] [5] [6] It has been reported that EPCs are rapidly mobilized after acute myocardial infarction, suggesting that the increase in circulating EPCs plays an important role in reduced myocardial damage in these patients through EPC-induced angiogenesis or cardiomyocyte regeneration. 7 Some interventions such as lifestyle modification, aerobic exercise, 8, 9 and pharmacological therapy (e.g., statin and erythropoietin) 10 ,11 also increase the number of EPCs, leading to improvement in injured vessels.
EPCs in peripheral circulation might reflect the pathogenesis of atherosclerosis and progression of cardiovascular disease (CVD). Indeed, several lines of evidence have shown relationships of number of EPCs with both cardiovascular risk factors and CVD. 12, 13 It has also been shown that a reduced circulating level of EPCs correlated with cardiovascular outcome. 14, 15 These findings suggest that cardiovascular risk factors are important to regulate EPCs and that the number of EPCs is a surrogate biological marker for atherosclerosis. However, the effect of each risk factor on the number of EPC is interpreted variously. [12] [13] [14] [15] [16] Therefore, we evaluated the relationships of circulating level of EPCs with cardiovascular risk factors and CVD.
Methods
Study subjects. We studied 135 consecutive hospitalized patients with CVD (mean age, 63.3 ± 15.6 years) from March 2005 to January 2006. To avoid the effects of acute reactive change on the number of EPCs, we excluded patients with acute myocardial infarction, unstable angina pectoris, acute thromboembolism, articles Aging and Hypertension in EPC acute inflammatory disease, and acute heart failure. As healthy controls, 25 healthy young men (mean age, 27.3 ± 9.1 years) were recruited. The study protocol was approved by the Ethics Committee of Hiroshima University Graduate School of Biomedical Sciences. Written informed consent was obtained from all subjects before participation.
Risk factors. Risk factor evaluation was performed according to following definition. We defined hypertension as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, and/ or the use of antihypertensive medication; hyperlipidemia as fasting serum low-density lipoprotein cholesterol ≥3.4 mmol/l and/or the treatment of lipid-lowering medications; and diabetes mellitus as fasting glucose level ≥7.0 mmol/l and/or a previous diagnosis of diabetes. Smoking consumption and family history dates were obtained from detailed questionnaires. The definition of smokers was those who fulfilled the pre-specified entry criteria: regular smoking history >5 pack years. One pack year was equivalent to 20 cigarettes smoked per day for 1 year. We defined nonsmokers as those who had never smoked. Family history was defined as a family history of CVD occurring before 65 years of age in first-degree relatives.
Measurement of EPCs.
The number of EPCs was analyzed by flow cytometry. Briefly, samples of venous blood were placed in tubes containing sodium EDTA (7 mg/ml) and in polystyrene tubes. The EDTA-containing tubes were chilled promptly in an ice bath. Peripheral blood mononuclear cells (MNCs) were immediately isolated by Ficoll density gradient centrifugation (AXIS-SHIELD). After thawing, 10 6 peripheral blood MNCs were incubated for 10 min with monoclonal antibodies against human fluorescein isothiocyanate-conjugated anti-CD45 (Miltenyi Biotec, Bergisch Gladbach, Germany), phycoerythrin-conjugated anti-AC133 (Miltenyi Biotec), allophycocyanine-conjugated anti-CD34 monoclonal antibody (Becton Dickinson Biosciences, San Jose, CA), and 7-aminoactinomycin D (Becton Dickinson Biosciences) for dead cells exclusion. To assess background, isotype controls were used as negative controls based on the species and immunoglobulin G subclass of each antibody. After incubation, erythrocytes were lysed, and the remaining cells were washed with phosphatebuffered saline, fixed in 2% paraformaldehyde, and analyzed on a fluorescence-activated cell sorting Calibur Flow Cytometer (Becton Dickinson Biosciences) according to the manufacturer's instructions (Figure 1) . Each analysis was performed until the measurement of 200 events in the target gate. To quantify the amount of CD34 + ACC133 + CD45 low cells, the MNC fraction was gated and analyzed for the expression of AC133 and CD45 cells. Only the AC133 + CD45 low cells were finally investigated for the count of CD34 + cells. The absolute number of EPCs per milliliter was calculated based on EPCs-to-MNCs ratio and the whole-blood cell count. To minimize any methodological Baseline clinical characteristics of the 135 patients and 25 healthy subjects are summarized in Table 1 . The number of EPCs and EPCs-to-MNCs ratio were significantly smaller in the patients group than in the healthy subjects group (1,047.4 ± 521.1/ml vs. 612.8 ± 461.6/ml, P < 0.0001; and 0.0534 ± 0.026% vs. 0.0258 ± 0.016% MNCs, P < 0.05, respectively) ( Figure 2 ). After adjustment for age, there was still a significant difference in the number of EPCs between the patients group and healthy subjects group.
relationship between number of ePcs and risk factors
The number of EPCs and EPCs-to-MNCs ratio significantly correlated with the number of risk factors (r = 0.424, P < 0.0001 and r = 0.469, P < 0.0001, respectively) ( Figure 3 ), whereas there was no correlation between the number of MNCs and risk factors. Age inversely correlated with the number of EPCs in all subjects (r = 0.566, P < 0.0001) (Figure 4) . We analyzed the relationship between number of EPCs and each other risk factor in the patients group. The numbers of EPCs were significantly smaller in patients with hypertension and diabetes mellitus than in patients without those diseases (762.6 ± 579.5/ml vs. 495.2 ± 297.7/ml, P < 0.01 and 666.8 ± 505.5/ml vs. 477.0 ± 290.4/ml, P < 0.05, respectively). There was no statistically significant difference in other risk factors, but family history of CVD tended to be associated with reduced number of EPCs (685.5 ± 526.4/ml vs. 524.1 ± 356.8/ml, P = 0.07) (Figure 5 , top). In the patients group, smoking did not alter articles
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the number of EPCs. Smokers included 47 subjects who had stopped smoking over 1 year (48%). There was no significant difference in the numbers of EPCs among the nonsmoker, current smoker, and smoking cessation groups (593.4 ± 375.3/ml vs. 521.2 ± 358.0/ml vs. 576.3 ± 362.2/ml). In the healthy subjects, the number of EPCs was less in smokers than in nonsmokers (1,274.6 ± 560.9/ml vs. 833.3 ± 347.5/ml, P < 0.05) (Figure 5, bottom) . Multivariate analysis revealed that age and hypertension were independent predictors of reduced number of EPCs, whereas none of the other parameters were independent predictors of reduced number of EPCs ( Table 2) .
relationship between number of ePcs and antihypertensive drugs
In view of the results of multivariate analysis, we evaluated the effects of antihypertensive drugs on number of EPCs. Reninangiotensin system (RAS) inhibitors showed an association with increase in number of EPCs (464.7 ± 252.1/ml vs. 617.5 ± 343.5/ml, P < 0.05), while calcium antagonists, diuretics, and β-blockers did not alter the number of EPCs in patients with hypertension ( Figure 6 ). The combination with RAS inhibitors and calcium antagonist tended to increase the number of EPCs, but the difference was not significant (486.8 ± 277.8/ml vs. 627.1 ± 343.2/ml, P = 0.09).
relationship between number of ePcs and cVd
Analysis of the relationship between number of EPCs and medical history of CVD in the patients group revealed that the The number of patients with each risk factor is described in table 1. NS, not significant.
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number of EPCs was reduced in patients with angina pectoris and patients with atherosclerotic peripheral arterial disease (598 ± 345/ml vs. 438 ± 225/ml, P < 0.05 and 547 ± 323/ml vs. 415 ± 225/ml, P < 0.05, respectively). Previous myocardial infarction and cerebrovascular disease did not alter the number of EPCs (Figure 7) . Multivariate analysis revealed that no medical history of CVD is an independent predictor for reduced number of EPCs.
discussion
In this study, we demonstrated that the number of cardiovascular risk factors correlated with the number of EPCs in patients with CVD. Aging and hypertension were independent predictors of reduced number of EPCs. RAS inhibitors, but not calcium antagonists, diuretics, or β-blockers, increased the number of EPCs in patients with hypertension. Analysis of the relationship between number of EPCs and each CVD revealed that patients with angina pectoris and patients with atherosclerotic peripheral arterial disease had significantly reduced numbers of EPCs.
An imbalance between magnitude of endothelium injury and capacity of endothelium repair is one of important factors for the process of development of atherosclerosis. Previous studies indicate that EPCs contribute to re-endothelialization as well as adult neovascularization. 2, 3 A reduced number of EPCs might not efficiently repair the injured endothelium, leading to vascular remodeling, platelet activation, inflammation, proliferation of smooth muscle cells, or loss of vasodilation. Therefore, impaired repair capacity of endothelial cells by reduced EPCs may lead to progression of atherosclerosis.
Our findings are consistent with results of previous studies showing that the number of EPCs had an inverse correlation with the number of total risk factors and that the patients group had a significantly lower number of EPCs than did healthy subjects. 12, 13 Some possible mechanisms by which the number of EPCs is decreased in relation to the number of risk factors for CVD have been postulated. The number of circulating EPCs is decreased mainly by reduced mobilization from bone marrow rather than depletion of stem cells. 17 It has been reported that mobilization of EPCs is regulated by various cytokines, such as vascular endothelial growth factor (VEGF), granulocyte colony-stimulating factor and stromal cell-derived factor-1, 4-6 and by bioactivity of nitric oxide (NO) in bone marrow. 18 This concept is accordance with the fact that the number of hematopoietic stem cells in bone marrow is maintained with aging. 19 Besides cell senescence and/ or apoptosis of EPCs, which are promoted by reactive oxygen species, also appear to be partly correlated with number of EPCs. 20, 21 In this study, aging and hypertension were found to be independent predictors of reduced number of EPCs. Both aging and hypertension are associated with decreased NO production 22, 23 and increased reactive oxygen species, resulting in reduction in the number of EPCs. In elderly patients, lower plasma VEGF level also appears to be related to reduced mobilization of EPCs from bone marrow. 24 Recently, Imanishi et al. 25 have reported that EPCs from hypertensive patients accelerated cell senescence and reduced telomerase activity, which might be linked to kinetics of EPCs after being mobilized into peripheral circulation. Other cardiovascular risk factors such as diabetes mellitus, hyperlipidemia, and smoking are also known to be related to reduced NO bioactivity or increased reactive oxygen species production. [26] [27] [28] Several studies, including this study, have shown that some of these factors are also correlated with reduced number of EPCs in univariate analysis. [12] [13] [14] [15] [16] However, because age and hypertension are potent and pioneering factors for predicting the number of EPCs, contributions of other cardiovascular risk factors should be excluded.
The number of EPCs was significantly increased in the RAS inhibitor-treated group but not in the group treated with calcium antagonists, β-blockers, and diuretics, suggesting that RAS inhibitors restore the number of EPCs in patients with hypertension. Several studies have demonstrated that RAS inhibitors, angiotensin II receptor blockers, and angiotensinconverting enzyme inhibitors, increase the number of EPCs in patients with type 2 diabetes mellitus 29 or stable coronary artery disease. 30 These results support our findings. Although the precise mechanism involved in the increase in EPCs by RAS inhibitors has not been revealed yet, it is well known that RAS inhibitors have beneficial effects on endothelial function through an increase in NO production. 31 The decrease in reactive oxygen species by RAS inhibitors may contribute to reduced NO inactivation in humans. 32 The increase in NO bioavailability by an increase in NO production and a decrease in NO inactivation should induce mobilization of EPCs. These findings suggest that RAS inhibitors have a pleiotropic effect on the repair of endothelial injury through activation of the NO/EPCs pathway.
Interestingly, smoking decreased the number of EPCs in the healthy subjects but not in patients with CVD. Previous studies have shown that smoking is a risk factor for reduced number of EPCs. 13, 14 The subjects in those studies were not divided into a patients group and healthy subjects group. In this study, all of the smokers in the healthy subjects group were current smokers, but the patients group included subjects who had stopped smoking. Kondo et al. 33 reported that smoking cessation restores the number of EPCs. However, there was no difference in the numbers of EPCs between nonsmoker, current smoker, and smoking cessation groups. The reason why smoking did not alter the number of EPCs in the patients group remains unclear. It is likely that smoking contributes to the development of atherosclerosis through a decrease in the number of EPCs.
In this study, patients with angina pectoris or atherosclerotic peripheral arterial disease had a significantly reduced number of EPCs. In contrast, history of myocardial infarction or cerebrovascular diseases did not alter the number of EPCs. The etiology of myocardial infarction and cerebrovascular diseases is thought to be thrombus or plaque rupture, and onset of these diseases is acute. 34 Atherosclerosis in patients with angina pectoris or peripheral arterial disease gradually progresses over a long period. The pathogenic mechanisms of atherosclerotic articles Aging and Hypertension in EPC diseases do not simply accord with the progression of atherosclerosis. In any case, decrease in the number of circulating EPCs should be involved in the development of endothelial impairment.
Study limitations: In early EPCs studies, the number of EPCs was mainly determined by counting adherent cells or colonyforming units on fibronectin-coated dishes using a culture method. 12, 35 In this method, however, the number of EPCs is altered by culture conditions (i.e., growth factors or fetal bovine serum) and by adhesive and proliferative potential. In addition, it takes a long time to obtain the results for clinical application. Analysis of the expression of a unique surface marker by flow cytometry is a sensitive and precise technique for counting the number of EPCs. Although the selection of surface markers is still an open question, we considered CD34 + AC133 + cells as EPCs, and CD45 low was selected for separating undifferentiated CD34 + AC133 + cells more clearly. 36 These cells underwent differentiation to mature endothelial cells in several studies. 37, 38 EPCs are considered as a heterogeneous population. 39 This fraction might not be entirely in accordance with EPCs, and be more like hemangioblasts. However, these cells are regarded as an immature progenitor cell population with potential to differentiate into mature endothelial cells. 40 Further investigation is needed to determine the real character of EPCs.
Although the number of subjects treated with β-blockers and diuretics was relatively small, our results showed that these antihypertensive drugs did not alter EPCs in patients with hypertension. Our data should be confirmed by further large-scale studies.
In this study, we did not measure the plasma concentration of VEGF. The measurement of circulating levels of VEGF would enable a more specific conclusion to drawn concerning the relationships between number of EPCs and risk factors. Further studies are needed to evaluate the relationships among number of EPCs, age, and plasma VEGF level.
In conclusion, our study showed an inverse correlation between cardiovascular risk factors and number of EPCs. Aging and hypertension were shown to be independent risk factors of reduced number of EPCs. These findings indicate that the number of EPCs should be useful as a surrogate biological marker for atherosclerosis. Risk factors of CVD and CVD per se induce not only endothelium injury but also impairment of the capacity of endothelium repair through a decrease in EPCs. It is important to select an appropriate intervention that is effective in increasing the number of EPCs or function of EPCs. Lifestyle modifications and pharmacological interventions have the potential for increasing EPCs as treatment for CVD associated with reduced EPCs. Further studies are needed to understand the biology of EPCs more clearly.
